{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-28T15:37:33.862852+00:00","company":{"ticker":"TRAX","cik":2091349,"company_name":"First Tracks Biotherapeutics, Inc."},"pagination":{"limit":100,"returned":8,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"AnaptysBio","detail":"supply","count":2,"first_seen":"2026-04-20T23:59:59+00:00","last_seen":"2026-04-20T23:59:59+00:00","evidence_fact_ids":[23824,23825]},{"display_name":"AnaptysBio, Inc.","detail":"lease","count":1,"first_seen":"2026-06-22T20:05:16+00:00","last_seen":"2026-06-22T20:05:16+00:00","evidence_fact_ids":[201558]}],"ma_counterparty":[{"display_name":"AnaptysBio, Inc.","detail":"disposition","count":1,"first_seen":"2026-04-20T23:59:59+00:00","last_seen":"2026-04-20T23:59:59+00:00","evidence_fact_ids":[23656]}]},"facts":[{"fact_type":"material_agreement","fact_key":"52ccfba0f0ec2adfc51706f96390628fc7b88f43","cik":2091349,"ticker":"TRAX","company_name":"First Tracks Biotherapeutics, Inc.","filed_at":"2026-06-22T20:05:16+00:00","payload":{"action":"entry","agreement_name":"Sublease","agreement_type":"lease","counterparty":"AnaptysBio, Inc.","effective_date":"2026-06-15","item_codes_triggered":["1.01"],"value_text":null},"claim":"First Tracks Biotherapeutics, Inc. entered into Sublease with AnaptysBio, Inc. (effective 2026-06-15).","evidence_excerpt":"On June 15, 2026, First Tracks Biotherapeutics, Inc. (the “Company”), entered into a Sublease Agreement (the “Sublease”) with AnaptysBio, Inc., a Delaware corporation (“AnaptysBio”), pursuant to which AnaptysBio agreed to sublease to the Company approximately 45,057 rentable square feet of space located at 10770 Wateridge Circle, San Diego, California 92121 (the “Premises”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-277504","anchor_url":"https://secwatch.observer/filing/0001193125-26-277504#claim-52ccfba0f0ec2adfc51706f96390628fc7b88f43","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526277504/0001193125-26-277504-index.htm"},{"fact_type":"earnings_release","fact_key":"a70f2374a4ec88513960da58d867bc5fd2abb1a5","cik":2091349,"ticker":"TRAX","company_name":"First Tracks Biotherapeutics, Inc.","filed_at":"2026-05-14T20:24:52+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss was $50.5 million for the three months ended March 31, 2026","period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-14","result_type":"reported_results","revenue_text":null},"claim":"First Tracks Biotherapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $50.5 million for the three months ended March 31, 2026.","evidence_excerpt":"On May 14, 2026, First Tracks Biotherapeutics, Inc. (“First Tracks”) issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-224124","anchor_url":"https://secwatch.observer/filing/0001193125-26-224124#claim-a70f2374a4ec88513960da58d867bc5fd2abb1a5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526224124/0001193125-26-224124-index.htm"},{"fact_type":"equity_issuance","fact_key":"192b723b49b3c5261ad70753a6bb1dd47766c6d5","cik":2091349,"ticker":"TRAX","company_name":"First Tracks Biotherapeutics, Inc.","filed_at":"2026-04-20T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":null,"effective_date":null,"item_codes_triggered":["3.02"],"purchaser":"AnaptysBio","security_type":"common_stock","shares_text":"29,100,802 shares of Common Stock"},"claim":"First Tracks Biotherapeutics, Inc. issued 29,100,802 shares of Common Stock of common stock to AnaptysBio.","evidence_excerpt":"the Company issued 29,100,802 shares of Common Stock to AnaptysBio in consideration for the transfer of certain entities that are part of AnaptysBio's biopharma business.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-164328","anchor_url":"https://secwatch.observer/filing/0001193125-26-164328#claim-192b723b49b3c5261ad70753a6bb1dd47766c6d5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm"},{"fact_type":"governance_change","fact_key":"a88750d1fb66a91688e3a72d2d96f4c2f9e9c9e2","cik":2091349,"ticker":"TRAX","company_name":"First Tracks Biotherapeutics, Inc.","filed_at":"2026-04-20T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":null,"item_codes_triggered":["5.03"],"summary_text":"Bylaws became effective in connection with the Spin-Off."},"claim":"First Tracks Biotherapeutics, Inc.: Bylaws became effective in connection with the Spin-Off.","evidence_excerpt":"Our Bylaws (the “Bylaws”) also became effective in connection with the Spin-Off.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-164328","anchor_url":"https://secwatch.observer/filing/0001193125-26-164328#claim-a88750d1fb66a91688e3a72d2d96f4c2f9e9c9e2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm"},{"fact_type":"governance_change","fact_key":"0a45008cb1e1fe1b7379f1bd6d2da84ffa83caca","cik":2091349,"ticker":"TRAX","company_name":"First Tracks Biotherapeutics, Inc.","filed_at":"2026-04-20T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":null,"item_codes_triggered":["5.03"],"summary_text":"Amended and Restated Certificate of Incorporation became effective in connection with the Spin-Off."},"claim":"First Tracks Biotherapeutics, Inc.: Amended and Restated Certificate of Incorporation became effective in connection with the Spin-Off.","evidence_excerpt":"We filed an Amended and Restated Certificate of Incorporation (the “Charter”) with the Secretary of State of the State of Delaware, which became effective in connection with the Spin-Off.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-164328","anchor_url":"https://secwatch.observer/filing/0001193125-26-164328#claim-0a45008cb1e1fe1b7379f1bd6d2da84ffa83caca","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm"},{"fact_type":"material_agreement","fact_key":"1b2ad13ee33d11bd021bf1c882ba15bd88328ac7","cik":2091349,"ticker":"TRAX","company_name":"First Tracks Biotherapeutics, Inc.","filed_at":"2026-04-20T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Transition Services Agreement","agreement_type":"supply","counterparty":"AnaptysBio","effective_date":null,"item_codes_triggered":["1.01"],"value_text":null},"claim":"First Tracks Biotherapeutics, Inc. entered into Transition Services Agreement with AnaptysBio.","evidence_excerpt":"the Company entered into a Separation and Distribution Agreement and a Transition Services Agreement (collectively, the \"Spin Agreements\") with AnaptysBio","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-164328","anchor_url":"https://secwatch.observer/filing/0001193125-26-164328#claim-1b2ad13ee33d11bd021bf1c882ba15bd88328ac7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm"},{"fact_type":"material_agreement","fact_key":"631470f7340f756208beb551f2662015c19a999e","cik":2091349,"ticker":"TRAX","company_name":"First Tracks Biotherapeutics, Inc.","filed_at":"2026-04-20T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Separation and Distribution Agreement","agreement_type":"supply","counterparty":"AnaptysBio","effective_date":null,"item_codes_triggered":["1.01"],"value_text":null},"claim":"First Tracks Biotherapeutics, Inc. entered into Separation and Distribution Agreement with AnaptysBio.","evidence_excerpt":"the Company entered into a Separation and Distribution Agreement and a Transition Services Agreement (collectively, the \"Spin Agreements\") with AnaptysBio","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-164328","anchor_url":"https://secwatch.observer/filing/0001193125-26-164328#claim-631470f7340f756208beb551f2662015c19a999e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm"},{"fact_type":"ma_transaction","fact_key":"3a58de5f73c71c9b0f1d5a66a86ee0ead88512a3","cik":2091349,"ticker":"TRAX","company_name":"First Tracks Biotherapeutics, Inc.","filed_at":"2026-04-20T23:59:59+00:00","payload":{"action":"disposition","closing_date":"2026-04-20","consideration_text":null,"counterparty":"AnaptysBio, Inc.","effective_date":"2026-04-20","item_codes_triggered":["2.01"]},"claim":"First Tracks Biotherapeutics, Inc. completed a disposition involving AnaptysBio, Inc. (closed 2026-04-20).","evidence_excerpt":"On the Distribution Date, AnaptysBio completed the Spin-Off.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-164328","anchor_url":"https://secwatch.observer/filing/0001193125-26-164328#claim-3a58de5f73c71c9b0f1d5a66a86ee0ead88512a3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm"}]}